CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

NCT03383965 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma

Interventions

BIOLOGICAL: ICAR30 T cells

Sponsor

Immune Cell, Inc.

Collaborators

[object Object]